Updated time: 2024-01-19 16:43:09
12A-1070131
2020-04-14
TW I733071、US 11,447,778 B2、JP 7397446、PCT filing
The TNF-a pathway plays as a double-edged sword in immune regulation. While excessive TNF-a causes cell apoptosis and triggers cytokine storms, an optimal TNF-a level is essential for innate immunity against bacterial infection and tissue repair. Therefore, timing and duration of intervention are keys to success for TNF-a pathway inhibition in the context of TNF-a signaling-related inflammatory diseases.
Our dimeric TNF-a aptamer blocks TNF-a function with high specificity and affinity (dissociation constant = 8 nM). When using PEG as linker, our TNF-a aptamer has adjustable inhibitory duration. It suppresses the TNF-a-induced cell apoptosis signaling at the early tissue injury phase and then be degraded and excreted without affecting the cell proliferating signaling at the late tissue repair phase. Furthermore, our TNF-a aptamer can be easily conjugated to imaging agents such as CT, MRI, ultrasound agent as diagnostic tool for in vivo TNF-a detection.
- Adjustable in vivo half-life
- Antidote can be easily designed with potentiate quick termination of its antagonistic effects whenever needed
- Easily manipulation for chemical conjugation to other components
- Topical (inhalation) and systematic drug delivery
- No antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects
- Low production cost and batch effects
- TNF-a signaling-related inflammatory diseases such as acute liver injury, acute lung injury, and acute respiratory distress syndrome
- In vivo detection of TNF-a level
Pan-Chyr Yang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A TNF-targeting aptamer with theranostic effects and its applications in TNF-related inflammatory diseases